The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due to overall disappointing third-quarter results, guidance cuts and pipeline setbacks. The sector has declined 9.5% in the past six months, underperforming the S&P 500 index, as seen in the chart below.Image Source: Zacks Investment ResearchNonetheless, given the continuous need for innovative medicines, the bio ...